Oncolytics Biotech Inc T.ONC

ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

[Noteable]

This is "exceptionally significant".

[Lesalpes29]

I agree. GL

[Noteable]

"Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc.

[canadafan]

Most importantly. There is no way, Onc would elevate the results to a verbal presentation if it was not good news. Bad news would be downplayed.  where it goes form there ( May 25th poster reveal), June 3 presentation? depends on many variable. being FDA input, potential partner ( co therapy), input. Few appreciate, the data ( Pelareorep & its abilities), is what drives

[westcoast1000]

Adding to what others noted, the conference organizers select the presentations to be given an oral time slot. That means someone is standing there speaking about the work, and then questions are asked, or there is a commenter that raises issues over the set of talk and then questions occur if time allows. It is a good opportunity. If it were a poster presentation, it is a smaller opportunity

[westcoast1000]

Just to add, not only is it a good opportunity for ONCY to talk about its recent results, it is also an early warning to all of us that the results are important enough to be given a good time slot in a Symposium. So the potential of failed results, or indifferent results as the focus of this talk have fallen in probability. This is a bullish signal on those results. 

[Noteable]

The "Harnessing the Breast Cancer Immune Response" symposium that ONCY is presenting at during ASCO is sponsored by the Breast Cancer Research Foundation which makes ONCY's oral presentation not only "significant" but even more "exceptional" given the nature of the subject matter.

[Buckhenry]

Let's not get all gitty and wet out panties here folks. We have seen this before. I hope something good comes out of this POS  finally.... but will keep a realistic outlook. Stock up 10% today and down  10% tomorrow... we have all seen that time after time. 

[lonc17]

Good to see some positive news from ONC. This should result in a steady increase in the share price over the next few weeks. 

[jimsenior]

I had considered an oral presentation and knew it was a longshot for anyone. Congratulations to all concerned. We may be looking at 2 AAs, and I do not mean batteries. If that is so, my idea of a pharma collaboration is not so far out. This would appear to be cutting edge, and I am wondering if anyone can tell me if biomarkers are an integral part of this. Great work to all concerned.

[jimsenior]

To be clearer, by pharma collaboration I meant the following. For example, Roche and Oncolytics apply for one AA, and Merck/ Pfizer and Oncolytics apply for a second AA. I know I am rushing the fences, but this is exciting and does not even consider CRC et al.

[westcoast1000]

Jimsenior, ONCY said they do not want to do that. They indicated they saw less risk (and obviously less complexity and management) with one partner rather than two. One might well pay more than two together. One could own the fundamental intellectual property if they bought us rather than having it parcelled out. 

[jimsenior]

@westcoast1000. Yes, I agree with you. I am just thinking out loud and there are no guarantees of anything. The patients are utmost in this equation. On the surface PDAC with tecentriq. mBC with avelumab. The players seem to be Roche, Pfizer and Merck. The three of them form an entity and make an offer to ONCY. Shareholders have a say; we have an offer from 3 pharmas but they have become an entity

[westcoast1000]

Jimsenior, ONCY said they do not want to do that. They indicated they saw less risk (and obviously less complexity and management) with one partner rather than two. One might well pay more than two together. One could own the fundamental intellectual property if they bought us rather than having it parcelled out.@

[Noteable]

 Amy Clark of U Penn is the Deputy director of clinical trials and an Assistant Prof in U penn medical school and hospitals. Because of her pedigree, she wouldn't be standing up at ASCO to present the results of a failed trial. The exact opposite. Since her credibility is paramount, Dr. Amy Clark will be presenting on the success of the Bracelet-1 study and how pelareorep is able to

[Noteable]

Should read: :  ....in advance of the addition of the PD-(L)1 immune checkpoint inhibitor (avelumab). Both Roche and Pfizer/Merck KGaA should be very pleased with these results and I would expect them to make a move on ONCY very soon.

[m00nsh0ts]

Why would you say that they would make a move now when Pfizer & Merck KGaA have already seen the results and I would assume with an NDA so has Roche. what's different now?

[Noteable]

The results will become public and open for all to see.

[m00nsh0ts]

Yes, that's the purpose of the abstract presentation for those that were not participants in the trial and did not request an NDA but how does that change things with Pfizer Merck KGaA and Roche, other than their FOMO?

[Noteable]

The larger picture extends well beyond just the well-known participants.

[Noteable]

Should read: The larger picture 'now' extends well beyond just the well-known participants.

[westcoast1000]

Why would you say that they would make a move now when Pfizer & Merck KGaA have already seen the results and I would assume with an NDA so has Roche. what's different now? Moonshot, I have wondered the same thing. One point that has been made is that the survival data seems to be important in terms of the amount of an offer. That has at least been implied strongly in the last big

[Noteable]

Because strategic delaying tactics are a part of large valuation deals involving multiple parties as witnessed in the US$43 Billion acquisition deal that Pfizer made for Seagen.

[jimsenior]

@Noteable. Amy Clark was involved with an Abstract on this trial. Feb 21, 2021. I shall leave it to you to comment further should you wish.  Best.

[jimsenior]

Correction; date was February 15, 2021.

[Noteable]

jimsenior - this is the abstract summary authored by Dr. Amy Clark et al. from February 15, 2021 that you are referring to and here is an excerpt .... "A subsequent window of opportunity study in early breast cancer has shown that pelareorep can indeed promote an adaptive immune response in breast cancer tissue, enhancing CD8+ T cell infiltration and upregulating PD-L1 expression

[westcoast1000]

Noteable, It is very helpful that you found the hypothesis for the study. Let us hope they stuck with the hypothesis and the results tell us something good about it. As you say, they are unlikely to be giving poor results in this event. 

[Noteable]

Westcoast- thank jimsenior for the heads-up. Cheers 

[fox7mf]

A nice little tidbit of excellent/important news. Oncy has been granted important realestate at ASCO, that certainly doesn't just go to any biotech. They could/should be presenting monumental data. Game changing. The BOD now must concentrate on delivering a steady stream of NR'S to bring shareholder value. What happens over the next month, and what is released at ASCO could very well lead

[Noteable]

"Being selected for an oral presentation at ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. [This should generate enough 'excitement' when this time comes]

[Noteable]

" ASCO is an immense honor that speaks to the importance of BRACELET-1's results to key opinion leaders and other critical stakeholders in breast cancer"  That should say enough.

[Noteable]

This privileged appearance and presentation at ASCO should "launch" ONCY's pelareorep into the next levels of M&A interactions with multiple Big Pharma companies.

[Noteable]

First stop US $3.20 and beyond.

[fox7mf]

2nd stop, $32 usd. Halt. Buyout at 150% premium. Congrats.

[Noteable]

Stll looking at US$10 Billion given Big Pharma's M&As 'sweet spot' of between US$5 and US$15 Billion.

[Noteable]

Calm down Quentin30 ... we already know what your motive happens to be on this message board.